Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.01497-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Jamese J Hilliard und 12 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Collegeville, Pennsylvania, USA. Hauptthemen laut MEDLINE: Anthrax, Bacillus anthracis, Anthrax Vaccines, Acenaphthenes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DOD | Defense Threat Reduction Agency (DTRA), GlaxoSmithKline (GSK).
Abstract (Originalsprache)
Bacillus anthracis is a Gram-positive Centers for Disease Control and Prevention category “A” biothreat pathogen. Without early treatment, inhalation of anthrax spores with progression to inhalational anthrax disease is associated with high fatality rates. Gepotidacin is a novel first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by a distinct mechanism of action and is being evaluated for use against biothreat and conventional pathogens. Gepotidacin selectively inhibits bacterial DNA replication via a unique binding mode and has in vitro activity against a collection of B. anthracis isolates including antibacterial-resistant strains, with the MIC 90 ranging from 0.5 to 1 µg/mL. In vivo activity of gepotidacin was also evaluated in the New Zealand White rabbit model of inhalational anthrax. The primary endpoint was survival, with survival duration and bacterial clearance as secondary endpoints. The trigger for treatment was the presence of anthrax protective antigen in serum. New Zealand White rabbits were dosed intravenously for 5 days with saline or gepotidacin at 114 mg/kg/d to simulate a dosing regimen of 1,000 mg intravenous (i.v.) three times a day (TID) in humans. Gepotidacin provided a survival benefit compared to saline control, with 91% survival ( P -value: 0.0001). All control animals succumbed to anthrax and were found to be blood- and organ culture-positive for B. anthracis . The novel mode of action, in vitro microbiology, preclinical safety, and animal model efficacy data, which were generated in line with Food and Drug Administration Animal Rule, support gepotidacin as a potential treatment for anthrax in an emergency biothreat situation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GSK, Collegeville, Pennsylvania, USA.
- US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA.
- Rutgers University School of Medicine, Newark, New Jersey, USA.
- Battelle Biomedical Research Center (BBRC), Columbus, Ohio, USA.
ORCID-Profile: Charles Jakielaszek, Cindy Fishman, Karen O'Dwyer
Förderung
- DOD | Defense Threat Reduction Agency (DTRA)
- GlaxoSmithKline (GSK)
Zitieren
APA
Hilliard, J. J., Jakielaszek, C., Mannino, F., Hossain, M., Qian, L., Fishman, C., Demons, S., Hershfield, J., Soffler, C., Russo, R., Henning, L., Novak, J., & O'Dwyer, K. (2024). Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01497-23
Vancouver
Hilliard JJ, Jakielaszek C, Mannino F, Hossain M, Qian L, Fishman C, et al. Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01497-23
BibTeX
@article{Hilliard2024,
author = {Hilliard, Jamese J and Jakielaszek, Charles and Mannino, Frank and Hossain, Mohammad and Qian, Lian and Fishman, Cindy and Demons, Samandra and Hershfield, Jeremy and Soffler, Carl and Russo, Riccardo and Henning, Lisa and Novak, Joseph and O'Dwyer, Karen},
title = {Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.01497-23}
}
EUVIMED